↩ Compound referenceLibido & ED

PT-141 (Bremelanotide)

5mg10mg
Reported, not recommended

Every figure below is transcribed from published literature (peptideprotocolportal.com, compiled 2026-09-29). None of it is a recommendation, a protocol, or a target, and none of it was written here. Whether any of it applies to a person is a question for a licensed clinician — who this is for explains why.

What the source says not to do

Quoted word for word from the notes column. Nothing here is paraphrased, and nothing has been added.

  • Not to exceed 20 units.
  • Consult doctor

All 2 presentations, as reported

The source lists this compound once per vial size. All of them are shown rather than one chosen for you, because the ranges differ between them.

Reported dose, frequency and route for PT-141 (Bremelanotide), by vial size.
VialDoseFrequencyRoute
5mg500mcg-1mg2 hrs before activity PRNSubQ
10mg500mcg-1mg2 hrs before activity PRNSubQ

The source's own notes

Reproduced in full, including the parts that are description rather than caution. Trimming this column for layout would remove its harm-reduction payload.

Not to exceed 20 units. Consult doctor


Before anything else

A compound's paperwork is the part you can actually verify. Reading a Certificate of Analysis and what a COA cannot tell you cover both halves of that, and inspecting a vial on arrival covers what to check before a vial is opened at all.